NCT04537975View on ClinicalTrials.gov

C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19

NAWithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 15, 2020

Primary Completion Date

November 15, 2020

Study Completion Date

January 15, 2021

Conditions

Continuous Renal Replacement TherapyPulmonary EdemaCOVID-19

Interventions

DEVICE

C2Rx

Hemofiltration

OTHER

Standard of Care (SOC)

Standard of care that excludes any protocol restrictions.

Sponsors

Lead Sponsor

SeaStar Medical

All Listed Sponsors

lead

SeaStar Medical

INDUSTRY

NCT04537975 - C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19 | Biotech Hunter | Biotech Hunter